AbbVieRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AbbVieImmunology-led pharma built around Skyrizi and Rinvoq after the Humira patent cliff. Entered obesity in March 2025 by licensing Gubra's long-acting amylin analog GUB014295 (GUBamy) for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation.
2021-Q2-2026-Q1
2021-Q2-2026-Q1
2012-2025
$ABBV
Late entrant to obesity. Licensed Gubra's long-acting amylin analog GUB014295 (GUBamy) in March 2025 for $350M upfront and up to $1.875B in milestones, taking global development and commercialisation. Amylin is the same mechanism class as Novo's cagrilintide and Zealand's petrelintide.